Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
30
MYNZ Quote, Financials, Valuation and Earnings
Last price:
$1.14
Seasonality move
:
-2.03%
Day range:
$1.09 - $1.28
52-week range:
$0.92 - $8.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.52x
P/B ratio:
1.87x
Volume:
355.3K
Avg. volume:
702.8K
1-year change:
-83.23%
Market cap:
$6.1M
Revenue:
$894K
EPS (TTM):
-$57.66
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Mainz Biomed NV has 1150% upside to fair value with a price target of $14.00 per share.
MYNZ vs. S&P 500
-
Over the past 5 trading days, Mainz Biomed NV has overperformed the S&P 500 by 7.3% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Mainz Biomed NV does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mainz Biomed NV has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mainz Biomed NV reported revenues of --.
Earnings Growth
-
Mainz Biomed NV has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mainz Biomed NV reported earnings per share of --.
Enterprise value:
5.3M
EV / Invested capital:
--
Price / LTM sales:
0.52x
EV / EBIT:
--
EV / Revenue:
5.97x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$144.1K
Return On Assets:
-350.28%
Net Income Margin (TTM):
-3297.86%
Return On Equity:
-2631.22%
Return On Invested Capital:
-607.71%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Income Statement | ||||||
| Revenue | $577.3K | $529.9K | $895.5K | $193.3K | $214.8K | |
| Gross Profit | $177.6K | -- | -$652.2K | $36.3K | -$104.9K | |
| Operating Income | -$9.7M | -- | -$26.6M | -$8.6M | -$6.6M | |
| EBITDA | -$11.3M | -- | -$25.5M | -$8M | -$6.4M | |
| Diluted EPS | -$38.96 | -- | -$65.57 | -$21.75 | -$9.80 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $186.4K | -- | -- | $9M | $7.8M | |
| Total Assets | $673.3K | -- | -- | $15.4M | $13.2M | |
| Current Liabilities | $702K | -- | -- | $9.2M | $5.9M | |
| Total Liabilities | $3.4M | -- | -- | $12.2M | $7.2M | |
| Total Equity | -$2.7M | -- | -- | $3.2M | $6M | |
| Total Debt | $2.5M | $2.1M | -- | $1.5M | $2.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2022-12-31 | 2023-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.2M | -$14.8M | -$21.9M | -- | -$4.7M | |
| Cash From Investing | $1.2M | -- | -$1.9M | -- | -$261.8K | |
| Cash From Financing | $10.6M | -- | $14.2M | -- | $3.5M | |
| Free Cash Flow | -$3.2M | -- | -$23.8M | -- | -$4.9M | |
MYNZ
Sector
Market Cap
$6.1M
$28.4M
Price % of 52-Week High
13.66%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.49%
1-Year Price Total Return
-83.23%
-16.67%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.09
200-day SMA
Sell
Level
$2.04
Bollinger Bands (100)
Sell
Level
1.22 - 1.68
Chaikin Money Flow
Sell
Level
-8.1M
20-day SMA
Buy
Level
$1.10
Relative Strength Index (RSI14)
Sell
Level
47.07
ADX Line
Buy
Level
12.18
Williams %R
Neutral
Level
-57.6271
50-day SMA
Sell
Level
$1.29
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Sell
Level
-16
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-13.1375)
Sell
CA Score
(Annual)
Level (-7.0439)
Sell
Beneish M-Score
(Annual)
Level (73.0217)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (11.481)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
Stock Forecast FAQ
In the current month, MYNZ has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MYNZ average analyst price target in the past 3 months is $14.00.
-
Where Will Mainz Biomed NV Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mainz Biomed NV share price will rise to $14.00 per share over the next 12 months.
-
What Do Analysts Say About Mainz Biomed NV?
Analysts are divided on their view about Mainz Biomed NV share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mainz Biomed NV is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Mainz Biomed NV's Price Target?
The price target for Mainz Biomed NV over the next 1-year time period is forecast to be $14.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MYNZ A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mainz Biomed NV is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of MYNZ?
You can purchase shares of Mainz Biomed NV via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mainz Biomed NV shares.
-
What Is The Mainz Biomed NV Share Price Today?
Mainz Biomed NV was last trading at $1.14 per share. This represents the most recent stock quote for Mainz Biomed NV. Yesterday, Mainz Biomed NV closed at $1.12 per share.
-
How To Buy Mainz Biomed NV Stock Online?
In order to purchase Mainz Biomed NV stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get MYNZ Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MYNZ
Sector
P/E ratio
--
23.89x
PEG ratio
0.00x
-0.01x
P/B ratio
1.87x
1.81x
Price / LTM sales
0.52x
1.58x
Growth Metrics
MYNZ
Sector
Revenue growth
--
4.62%
Earnings growth
--
10.7%
Revenue (5-year growth)
26.01%
6.5%
Earnings forecast
-$2.80
-$0.21
Profitability
MYNZ
Sector
Profitability FY 2024
-$442.2K
$3.6M
Return on invested capital
-607.71%
-31.84%
Return on assets
-350.28%
-27.96%
Return on equity
-2631.22%
-37.63%
Earnings Date
Last Earnings Date
Dec
24
Next Earnings Date
Dec
24
Estimated Next Earnings Date
Mar
25
Balance Sheet
MYNZ
Sector
Total cash
$977.8K
$26.4M
Short term investments
--
$25.7M
Total assets
$13.2M
$76.9M
Long term debt
$6.9M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
